You are viewing the site in preview mode
Skip to main content
|
Patients
|
Number
|
|---|
|
MDS
|
39
|
|
Gender
|
|
Male/Female
|
18/21
|
|
Age (years), median (range):
|
69 (27–89)
|
|
WHO classification
| |
|
RA/RARS/RCMD
|
04/07/20
|
|
RAEB-1/RAEB-2
|
07/01
|
|
Cytogenetic riska
|
|
Very good/good
|
01/32
|
|
Intermediate
|
02
|
|
Poor/very poor
|
01/01
|
|
No growth
|
02
|
-
Abbreviations: MDS myelodysplastic syndromes, WHO World Health Organization, RA refractory anemia, RARS refractory anemia with ringed sideroblasts, RCMD refractory cytopenia with multilineage dysplasia, RAEB-1 refractory anemia with excess blast-1, RAEB-2 refractory anemia with excess blast-2, BM bone marrow. aIn MDS cohort, karyotype findings included very good : –Y (n = 1); good: normal (n = 32), intermediate: +8 (n = 1); other (n = 1); poor: 3 abnormalities (n = 1), and very poor: >3 abnormalities (n = 1)